Thinking outside of the box: sales insight using AI

Improve your sales insight using AI

Will 2019 be the year in which pharma sales and marketing teams use augmented intelligence to successfully exploit infinite data? Buzz Lightyear made his first...

OBN appoints new Chairman and Non-Executive Director

OBN, the membership organisation supporting the UK’s innovative life sciences companies, announces the following changes to its Board. Bill Fleming has been appointed the new...
Simon Toy on addressing common challenges in the workplace

How to address common challenges in the workplace

Is your organisation 2019 ready? Simon Toy, Managing Director of Performance Associates discusses addressing common challenges in the workplace As 2018 winds to an end, many...
Sandy Lindsey National Implementation Lead Manager, Vaccines, MSD

What is the role of a National Implementation Lead Manager?

Sandy Lindsey, National Implementation Lead Manager, Vaccines, MSD, joint winner of the Account Project Pf Award 2018, on how her role is really all...
Susanne Schaffert, Ph.D., President, AAA, an established Novartis executive, named new CEO, Novartis Oncology

Novartis announces new CEO of Oncology Business Unit

Novartis have appointed Susanne Schaffert, Ph.D., as the new CEO of Novartis Oncology  Novartis announced that Susanne Schaffert, Ph.D., currently President, Advanced Accelerator Applications (AAA), a...
transforming engagement for precision medicine with the cloud

Maxwellia expand their team with two new appointments

Maxwellia has expanded their team of switch experts with two new appointments following their relocation to the Alderley Park Accelerator. 
Vonnie Alexander as non-executive director

Synergy Vision appoints Vonnie Alexander as non-executive director

Synergy Vision is gearing up for global growth with the appointment of Vonnie Alexander as non-executive director.  This comes after the Australian office doubled business...
Woman interviewing man at a desk demonstrating a successful key account manager

How to be a successful key account manager

Pf asked two consultants from top pharma recruitment consultancies for their views on what it takes to be a successful key account manager.   Andy Boyd, Senior...
Dr Annalisa Jenkins & Lord Michael Grade become advisors to AKL

Dr Annalisa Jenkins & Lord Michael Grade become advisors to AKL

AKL Research and Development (AKLRD), a company developing an investigational osteoarthritis (OA) medicine, has announced the appointment of Dr Annalisa Jenkins and Lord Michael...
CF Future Care

CF Future Care: Putting people with CF in the driving seat

Dr Su Madge is the driving force behind a digital platform called CF Future Care, putting people with cystic fibrosis (CF) in the driving...

Latest articles

Oral health has been isolated from traditional healthcare and health policy for too long fuelling an oral health crisis according to a Lancet Series.

Big Sugar and neglect by global health community fuel oral health crisis 

Oral health has been isolated from traditional healthcare and health policy for too long, despite the major global public health burden of oral diseases,...
New statistics show decrease in animals used for R&D

New statistics show decrease in animals used for R&D

The Home Office has released its annual statistics on animals used in research in Great Britain. It shows 3.52 million procedures were carried out...
New insight into microRNA function has been published by scientists at the University of Eastern Finland and the University of Oxford.

New insight into microRNA function can give gene therapy a boost

New insight into microRNA function has been published by scientists at the University of Eastern Finland and the University of Oxford. They have shown that...

Popular articles

pain relief patch released by nurofen

Nurofen launches a 24 hour ibuprofen pain relief patch

Nurofen announces the launch of the UK’s only 24 hour clinically proven pain relief patch containing ibuprofen.  Despite body pain being among the most commonly...
NICE has approved a first-in-class gene silencing therapy for hereditary amyloidosis.

Gene silencing therapy for hereditary amyloidosis approved by NICE

NICE has approved a first-in-class gene silencing therapy for hereditary amyloidosis. RNA interference (RNAi) therapeutics company, Alnylam UK Limited has welcomed a decision from the...
AstraZeneca to appeal NICE's osimertinib decision

AstraZeneca to appeal NICE’s osimertinib decision

AstraZeneca to appeal NICE's osimertinib decision following it not being recommended for use within NHS England. AstraZeneca will appeal a decision by the National Institute...

Top 5 R&D hubs in the UK

Read this cover story in the June issue of Pf Magazine here.    Join us on a tour of inspirational research and development centres. ...

How to write a standout CV

The job market is getting more competitive by the day, as highly-qualified candidates fiercely compete for the top jobs. A carefully constructed CV is...